



Cardiovascular Outcomes Associated with Second-Line Agents for Type 2 Diabetes Mellitus

October 8, 2018

Agenda

- Welcome
- Background and Goals for the Day
 - PCORI's Exploration of Second-Line Treatments for T2DM
 - Focus on Observational Study: Examination of Feasibility
 - Questions to Guide Our Discussion
- Discussion
- Summary and Closing Remarks